Effect of epithelial growth factor on matrix metalloproteinase-2 and E-cadherin/β-catenin expression in an in situ model of tumorigenesis

Abstract

The aim of the present study was to analyze the in vitro effect of various doses of epidermal growth factor (EGF; 5 and 10 ng/ml) on matrix metalloproteinase-2 (MMP-2) secretion and E-cadherin/β-catenin expression by co-cultured cells that mimic an in situ carcinoma ex-pleomorphic adenoma, where benign myoepithelial cells from a pleomorphic adenoma surround malignant epithelial cells. EGF was supplemented in various doses and the effects were evaluated following four days of cell culture. ELISA was performed to determine MMP-2 secretion levels. Gene expression for E-cadherin and β-catenin was analyzed using quantitative polymerase chain reaction. The results revealed that E-cadherin expression decreased when the cells were supplemented with 5 ng/ml EGF. ELISA results indicated that MMP-2 secretion increased when EGF was supplemented at concentrations of 5 and 10 ng/ml. The present findings demonstrated that EGF may be involved in the epithelial-mesenchymal transition process via altering the E-cadherin/β-catenin complex and increasing MMP-2 secretion, which may then favor the dissolution of the basement membrane to the benefit of malignant cell clusters, contributing to the development of an invasive phenotype in this in vitro model of tumorigenesis.

Introduction

Tumor progression is a complex phenomenon that involves the interaction between tumor cells and the surrounding tissues, promoting a plastic phenotype referred to as the epithelial-mesenchymal transition (EMT) (1). This process involves alterations in cell-cell and cell-matrix interactions, and consequently the acquisition of a motile phenotype (1,2). The molecules involved in cell-cell interactions assume a significant role in physiological events and pathological conditions such as inflammatory and neoplastic processes (2). Among such molecules, calcium-dependent transmembrane glycoproteins (epithelial-cadherin) expressed in epithelial tissues, termed E-cadherins, are highlighted (3).

E-cadherin is associated with a group of intracellular proteins termed catenins, which bind to the actin filaments of the cytoskeleton (3). Cadherins and catenins form a single functional complex so that the deletion or mutation of one of these proteins may result in a loss of function or the disruption of cell-cell adhesion (4). Studies have revealed that the E-cadherin/β-catenin complex (EβC) is a key regulatory factor required for the maintenance of normal intercellular adhesion in carcinomas, acting as an invasion suppressor molecule (1,2,5). Consequently, a loss of EβC function allows or increases the risk of neoplastic invasion of the underlying normal tissue (5). Changes to E-cadherin expression patterns may, therefore, be a vital step in the development and progression of malignant tumors (5,6).

During the early stages of glandular tumors in situ, malignant luminal cells are surrounded by an intact layer of myoepithelial cells (7). However, this condition is short-lived, as myoepithelial cells rapidly disappear (8,9). A number of hydrolytic enzymes, released either by the tumor cells or by cells surrounding the tumor, combined with certain growth factors may favor disruption of the basement membrane, contributing to EMT (10). Matrix metalloproteinases (MMPs) act by degrading almost all components of the basement membrane and the extracellular matrix (ECM) (11). In malignant disease, metastasis-associated MMP overexpression has been reported to be associated with cytokines such as epidermal growth factor (EGF), which in turn may serve a role in modulating a developing metastatic potential in neoplastic cells (12).

EGF has been extensively investigated in invasive tumor phenotypes, and several in vitro studies have demonstrated the proliferative effect of EGF on a variety of cell types (4,13,14). Additionally, EGF performs an essential role in promoting a migratory phenotype, even in benign cells (4,14). When EGF binds to its receptor, E-cadherin is internalized from the cell membrane, reducing cell-cell contact, which in turn weakens the epithelial layer and induces EMT (15,16). EGF has been revealed to upregulate a number of MMPs in squamous cell carcinoma cells, as well as in myoepithelial cells (15).

Considering the importance of myoepithelial cells to the invasive behavior of cancer cells in salivary gland neoplasms (17,18), the present study aimed to evaluate the role of EGF on E-cadherin/β-catenin gene expression and MMP-2 secretion in an in vitro model of tumorigenesis, which mimics a situation where in situ neoplastic cells of oral carcinoma are surrounded by benign myoepithelial cells (19).

Materials and methods

Cell culture

The present study was approved by the Research Ethics Committee of the São Leopoldo Mandic Dental Institute and Research Center (Campinas, Brazil; approval no. 1.468.890/2016). Benign myoepithelial cells were obtained from explants of excised salivary gland pleomorphic adenoma (PA), as previously described (18).

Cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) supplemented with 1% antimycotic-antibiotic solution (10,000 U/ml penicillin, 10 mg/ml streptomycin and 25 mg/ml amphotericin B in 0.9% sodium chloride; Sigma-Aldrich; Merck KGaA) containing 10% donor calf serum (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Cells were then seeded onto 60-mm diameter plastic culture dishes (110 cells/mm²) and incubated under standard cell culture conditions (37°C, 100% humidity, 95% air and 5% CO₂). Once 100% confluence was reached, the cells were detached using 0.05% trypsin and subcultured at a density of 110 cells/mm² in 20 µg/ml fibronectin substratum (Sigma-Aldrich; Merck KGaA). The cells were then seeded either onto polystyrene plates or 13-mm coverslips for subsequent experiments. The benign myoepithelial cells from PA seeded either on the polystyrene plates or coverslips were cultured in DMEM for 24 h (37°C, 100% humidity, 95% air and 5% CO₂) prior to supplementation with malignant conditioned medium, which contains floating vital malignant cells that have lost their ability to adhere to polystyrene, and according to the method described by Martinez et al (18,19), is likely to contain malignant stem cells.

For cell induction using malignant conditioned medium in vitro, CAL27 squamous cell carcinoma cells were obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured as aforementioned. Cell culture medium (DMEM) was changed 48 h prior to use. Benign myoepithelial cells cultured in DMEM for 24 h were then incubated for four days with the unfiltered malignant conditioned medium (37°C, 100% humidity, 95% air and 5% CO₂), which contained non-adhered malignant epithelial cells. EGF was subsequently added at 5 or 10 ng/ml (BD Biosciences, San Jose, CA, USA). As a control group, myoepithelial cells were cultured in conventional non-conditioned DMEM.

Indirect immunofluorescence

Cells grown on coverslips were fixed in absolute methanol for 6 min at −20°C and rinsed with PBS, followed by blocking with 1% bovine albumin (catalog no. A2058; Sigma-Aldrich; Merck KGaA) in PBS for 30 min at room temperature. Polyclonal rabbit E-cadherin (catalog no. H-108; dilution, 1:50; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and monoclonal mouse β-catenin (catalog no. 610154; dilution, 1:50; BD Biosciences) primary antibodies were incubated for 1 h at room temperature. Control staining was performed using PBS in place of the primary antibody. The secondary antibody used was either biotinylated goat anti-rabbit (catalog no. 4050-08; dilution) or goat anti-mouse IgG (catalog no. 1031-08; dilution, 1:150) (both from Vector Laboratories, Inc., Burlingame, CA, USA), which were incubated for 30 min at room temperature. Fluorescein-streptavidin conjugate (catalog no. SA-5001; dilution, 1:150; Vector Laboratories, Inc.) was used for the second step. The preparations were rinsed and mounted using DAPI-associated Vectashield® (catalog no. H-1200; Vector Laboratories, Inc.) and the slides were maintained at 4°C for up to 24 h to prevent loss of fluorescence. The images were assessed immediately after staining using a Zeiss Axioskop 2 conventional fluorescence microscope (original magnification, ×400; Carl Zeiss MicroImaging GmbH, Jena, Germany) equipped with 63X Plan Apochromatic 1.4NA and 100X Plan Apochromatic 1.4NA objectives (Carl Zeiss MicroImaging GmbH).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA was isolated from the cells cultured under differing conditions using TRIzol® reagent (Molecular Research Center, Cincinnati, OH, USA). The RNA samples were treated with DNase (1:1, DNase I, RNase-free kit; catalog no. EN0521; Fermentas; Thermo Fisher Scientific, Inc.). Reverse transcription was performed using the Superscript III First-Strand cDNA Synthesis kit (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. The primer sets were as follows: β-catenin forward, 5′-GCAGTTCGCCTTCACTATGGA-3′ and reverse, 5′-GACAAAGGGCAAGATTTCGAATC-3′; E-cadherin forward, 5′-TCATGAGTGTCCCCCGGTAT-3′ and reverse, 5′-TCAAACACGAGCAGAGAATCATAAG-3′; GAPDH (used as the internal reference gene) forward, 5′-TGGCAAAGTGGAGATTGTTGCC-3′ and reverse, 5′-AAGATGGTGATGGGCTTCCCG-3′. RT-qPCR was performed using a 7500 Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) with SYBR-Green/ROX (Maxima; Fermentas; Thermo Fisher Scientific, Inc.), as the detection dye. Cycling conditions were as follows: 10 min at 95°C followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. Quantification of the data was performed using the 7500 software (7500 Fast Red Time PCR systems v2.0.6; Applied Biosystems; Thermo Fisher Scientific, Inc.) and the relative expression levels were calculated according to the comparative Cq method, as 2^−ΔΔCq (20). Each qPCR experiment was repeated three times.

ELISA

MMP-2 quantification was performed using the human MMP-2 ELISA kit (catalog no. DY902; R&D Systems, Inc., Minneapolis, MN, USA). Coating containing the capture antibody and blocking were provided in the kit and performed according to the manufacturer's protocol. The reactions were performed on a 96-well plate (catalog no. 80040LE 0903; Apogent Technologies, Inc., Milwaukee, MI, USA), according to the manufacturer's recommendations. Supernatant obtained from the cell cultures were harvested and centrifuged at 5,000 × g at 4°C for 15 min, 100 µl. The wells were then rinsed three times with washing buffer (0.05% Tween-20 in PBS, pH 7.2) prior to adding the standard (provided in the kit) and supernatant in duplicate wells. Following incubation for 2 h at room temperature, the plates were washed again and incubated with 100 µl of the detection antibody at room temperature for 2 h. The plates were then rinsed three times (0.05% Tween-20 in PBS, pH 7.2), treated with 100 µl of streptavidin-horseradish peroxidase for 20 min at room temperature and rinsed three times with washing buffer (0.05% Tween-20 in PBS, pH 7.2). Substrate solution (100 µl; provided in the kit) was added to each well and incubated for 15 min in the dark at room temperature. The reaction was stopped by adding 50 µl stop solution (provided in the kit), and the color was measured at 450 nm, using an automated microplate spectrophotometer (Epoch), associated with the software GenS (v1.10.8) (both from BioTek Instruments, Inc., Winooski, VT, USA). Total MMP was quantified in ng/ml. Results were calculated using the standard curves created in each assay. The ELISA assays were performed in a blind manner and in triplicate.

Statistical analysis

Data are expressed as the mean ± standard deviation. In order to compare the results between distinct conditions, one-way analysis of variance was used with Tukey's post hoc test. P<0.05 was considered to indicate a statistically significant difference. All statistical calculations were performed with GraphPad Prism v 6.0 software (GraphPad Software, Inc., La Jolla, CA, USA).

Results

Indirect immunofluorescence of E-cadherin and ß-catenin

Indirect immunofluorescence to E-cadherin and β-catenin in the co-cultured cells under different conditions is illustrated in Fig. 1. E-cadherin and β-catenin were observed to be immunoexpressed in the cytoplasm of the malignant cells under all studied conditions. No immunostaining was observed in the myoepithelial cells, even following EGF supplementation.

Figure 1.

Immunostaining for E-cadherin and β-catenin in myoepithelial cells (*) and in malignant cells (**) after four days of cell culture without EGF (control) or with 5 and 10 ng/ml EGF. E-cadherin and β-catenin were immunoexpressed in the cytoplasm of malignant cells under all studied conditions. No immunostaining was observed in the myoepithelial cells. Nuclei stained with DAPI appear in blue. Scale bar, 50 µm. EGF, epidermal growth factor.

mRNA E-cadherin and ß-catenin expression

In order to quantify the results observed using immunofluorescence, the expression of E-cadherin and β-catenin was assessed using qPCR (Fig. 2) following EGF supplementation. E-cadherin expression was significantly downregulated in the cells treated with 5 ng/ml EGF, when compared with the control group (P<0.05; Fig. 2A), which was statistically similar to the group treated with 10 ng/ml EGF (P>0.05). No difference was observed in β-catenin mRNA expression levels following EGF supplementation (Fig. 2B), as compared with the control (P>0.05).

Figure 2.

Quantitative polymerase chain reaction analysis of (A) E-cadherin and (B) β-catenin transcript levels without (control) and with 5 and 10 ng/ml EGF. GAPDH was used as the internal reference gene. The data are representative of three independent experiments conducted in duplicate (mean ± standard deviation). *P<0.05, compared with the control group. EGF, epidermal growth factor.

MMP-2 protein secretion

MMP-2 levels in the co-cultured cells under different conditions are presented in Fig. 3. The results indicated an increase in MMP-2 secretion in the cells following supplementation with 5 and 10 ng/ml EGF, when compared with the control group (P<0.05).

Figure 3.

MMP-2 expression levels without EGF (control) or with 5 and 10 ng/ml EGF. The values are representative of three independent experiments conducted in duplicate (mean ± standard deviation). *P<0.05, compared with the control group. MMP-2, matrix metalloproteinase-2; EGF, epidermal growth factor.

Discussion

Metastasis is a process that involves several sequential and interrelated steps, including detachment, migration, invasion and adhesion, and in this context, the tumor microenvironment has been widely studied and is considered an important factor in the so named ‘invasion-metastasis cascade’ (21,22). Growth factors are secreted by normal and cancerous cells within the tumor microenvironment, and are involved in tumor initiation and progression (4). EGF has been revealed to be associated with cell proliferation and migration in contexts such as salivary gland tumors (17) and EMT (15).

EMT is a result of paracrine signaling by stromal-derived factors, and is also a potential source of cells within the stromal compartment; cross-talk between neoplastic and stromal cells may affect the production and secretion of a number of molecules and matrix proteases, including the E-cadherin/β-catenin complex, which is responsible for maintaining adhesive properties, and MMPs, which have previously been implicated in degrading components of the basement membrane (10).

In the present in vitro study, MMP-2 secretion and E-cadherin/β-catenin expression were analyzed following four days of cell culture, wherein myoepithelial cells, mimicking an in situ condition, surrounded carcinoma cells. As co-culture time progresses, benign cells begin to disappear until only malignant cells are left (8), and such interactions between neoplastic cells and the stroma can no longer be detected. This behavior is associated with basement membrane disruption through the action of MMPs, which culminates in EMT-associated invasion (15). Such findings corroborate an invasive behavior by the malignant cells, which occurs in the presence of EGF downregulating E-cadherin expression and increasing MMP-2 secretion.

In epithelial cells, EGF has been associated with increasing MMP secretion, contributing to a metastatic phenotype by modifying certain ECM components and promoting a motile behavior, which is typical of EMT (12). In addition, MMP-2 is known to promote modifications to cell morphology and phenotype in vitro (13), which can directly affect cell adhesion (11). Furthermore, MMP-2, which is one of the major enzymes involved in degrading collagen types I and IV as well as the ECM, is overexpressed in highly metastatic tumors, demonstrating the importance of this molecule in cancer invasion and metastasis (23).

E-cadherin expression is impaired in a number of tumor types, and its loss from the cell surface due to genetic or epigenetic events leads to disruption of cell contacts, tumor cell detachment, shape change and local invasion, all of which are events known to initiate EMT (24). In this setting, β-catenin is considered as one of the most important factors involved in decreasing cell-cell interactions in malignant epithelial cells (25). In an environment of degradation and destabilization of cell-cell adhesion and decreased E-cadherin expression, β-catenin is released into the cytoplasm causing it to accumulate and eventually lead to nuclear translocation (25). Cadherin switching is a hallmark of EMT, where E-cadherin can be replaced by an abnormal expression of N-cadherin without changes in E-cadherin levels (26). This event may be affected by cytokines and growth factors (27). It has previously been reported that EGF is also involved in regulating cell adhesion in several solid malignancies (28), and that EGF stimulation causes E-cadherin relocation from the membrane to the perinuclear area during EMT in head and neck squamous cell carcinoma (29).

Dynamic evaluation of certain factors, such as EGF, with regard to E-cadherin/β-catenin expression may yield data concerning key biological processes in tumorigenesis in vitro. However, the use of E-cadherin/β-catenin as prognostic markers in salivary gland tumors containing myoepithelial cells, for instance, may not necessarily generate definitive predictive values (30). Furuse et al (30) demonstrated that such molecules may be immunoexpressed in normal salivary glands as well as in malignant neoplastic tissues, be it invasive or non-invasive. In such cross-sectional studies, biological timing is difficult to predict histologically. Additionally, although a quantitative difference may exist between the physiological and neoplastic expression of E-cadherin/β-catenin, as demonstrated in the present in vitro study, such differences are likely to go undetected using qualitative methods.

In conclusion, the present study demonstrated that EGF performs an important role in the EMT process by altering the expression of the E-cadherin/β-catenin complex and increasing MMP-2 secretion. This could, in turn, favor the dissolution of the basement membrane, aiding the maintenance of malignant cell clusters in detriment of stromal cells and encouraging an invasive phenotype, based on this in vitro model of tumorigenesis.